Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1073781 | 0.91 | ALK (0.49) | SMN1; SMN2RAB9ANPC1HPGDNPSR1 | |
| Trifluoroacetic Acid SCHEMBL4360587 | 0.87 | ALK (0.45) | SMN1; SMN2RAB9ANPC1HPGDNPSR1 | |
| SCHEMBL13634102 | 0.87 | JAK2 (0.41) | SMN1; SMN2NPC1HPGDNPSR1LMNA | |
| SCHEMBL13633236 | 0.83 | ALK (0.42) | JAK2ALK | |
| SCHEMBL13633131 | 0.83 | ALK (0.43) | JAK2ALK | |
| SCHEMBL13633063 | 0.83 | ALK (0.41) | HPGDKDM4EJAK2MAPTALK | |
| SCHEMBL13634016 | 0.82 | JAK2 (0.43) | RAB9ANPC1NPSR1JAK2MAPT | |
| SCHEMBL13633235 | 0.82 | ALK (0.44) | SMN1; SMN2RAB9ANPC1HPGDLMNA | |
| SCHEMBL13633078 | 0.82 | ALK (0.40) | SMN1; SMN2TP53JAK2MAPTALK | |
| SCHEMBL13633079 | 0.82 | ALK (0.44) | JAK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | SMN1; SMN2 4274/4885RAB9A 1998/4885NPC1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.